AOAlison I. Orvin

Alison I. Orvin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alison I. Orvin has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of Oral Cephalosporin and Penicillin Step-Down Therapy for the Treatment of Gram-Negative Blood Stream Infections: A Retrospective Observational Study

    by Bethany Volkmar, Caitlin C. Akerman, Alison I. Orvin

    Background: Oral step-down therapy for the treatment of gram-negative blood stream infections (GNBSIs) has been shown to be noninferior to full courses of intravenous (IV) therapy. Studies comparing oral fluoroquinolones, sulfamethoxazole-trimethoprim (SMX-TMP), and beta-lactams have reported similar treatment outcomes, but beta-lactam groups have been small, and efficacy has been questioned given lower oral bioavailability. Objective: This study aims to evaluate the safety and efficacy of oral cephalosporins compared with penicillins for step-down therapy for the treatment of GNBSI. Methods: This was a retrospective study in adult patients admitted for Enterobacterales GNBSI that were transitioned from IV antibiotics to an oral beta-lactam. The primary outcome was treatment failure. Secondary outcomes included components of the primary outcome, microbiological failure, antibiotic-associated adverse drug events (ADEs), and Clostridioides difficile infection (CDI). Results: Overall, 280 patients with GNBSI with step-down to an oral penicillin ( n = 140) or cephalosporin ( n = 140) were included. More patients in the cephalosporin group had a urinary source of infection (87.9% vs 62.1%, P < 0.001) and urinary abnormalities (40% vs 28.6%, P = 0.044). Treatment failure with oral cephalosporins was noninferior to penicillins (7.1% vs 7.1%; 95% confidence interval [–6.4, 6.4], P = 0.002). No significant differences were found for microbiological failure, antibiotic-associated ADEs, or CDI. Conclusion and Relevance: Oral cephalosporins were noninferior to oral penicillins as step-down therapy for Enterobacterales GNBSI. This represents the first comparison of oral beta-lactams for the treatment of GNBSI.

  • Evaluation of Sequential Oral Versus Intravenous Antibiotic Treatment of Enterococcus faecalis Bloodstream Infections

    by Carly Loudermilk, Joshua Eudy, Stephanie Albrecht, Cara N. Slaton, Stefanie Stramel, Patrick Tu, Benjamin Albrecht, Sarah B. Green, Jeannette L. Bouchard, Alison I. Orvin, et al.

    Background: Intravenous (IV) antibiotics have historically been considered standard of care for treatment of bloodstream infections (BSIs). Recent literature has shown sequential oral (PO) therapy to be noninferior to IV antibiotics for certain pathogens and disease states. However, a gap exists in the literature for BSI caused by Enterococcus faecalis. Objective: To compare outcomes of definitive sequential PO therapy to definitive IV therapy in patients with E faecalis BSI. Methods: Multicenter, retrospective, matched cohort study of adult patients with at least one blood culture positive for E faecalis from January 2017 to November 2022. Patients with polymicrobial BSI, concomitant infections requiring prolonged IV antibiotic therapy, those who did not receive antibiotic therapy, and those who died within 72 hours of index culture were excluded. Subjects were matched based on source of infection in a 2:1 (IV:PO) ratio. The primary outcome was a composite of all-cause mortality and treatment failure. Secondary outcomes included hospital length of stay (LOS), antibiotic duration, and 30-day readmission rate. Results: Of the 186 patients who met criteria for inclusion, there was no statistically significant difference in the primary composite outcome for PO compared to IV therapy (14.5% vs 21.8%; OR 0.53 [0.23-1.25]) or 30-day readmission (17.5% vs 29%; OR 0.53 [0.25-1.13]). Hospital LOS was significantly longer in patients receiving IV-only therapy (6 days vs 14 days; P < 0.001). Conclusion and Relevance: Sequential oral therapy for E faecalis BSI had similar outcomes compared to IV-only treatment and may be considered in eligible patients.


  • Open Access

    An Incidental Finding of Whipple’s Disease Masquerading as Nonspecific, Long‐Standing Symptoms

    by Thomas Tuggle, Alison I. Orvin, Christian Caveness, Christopher Ingram

    Whipple’s disease is a rare bacterial infection that is often present for years prior to diagnosis. Symptoms are nonspecific in the early stages of presentation and are primarily gastrointestinal in nature. The disease may progress with more systemic symptoms including arthralgia, fever, lymphadenopathy, cardiovascular disease, and central nervous system involvement. This case describes a man with a history of long‐standing, nonspecific symptoms who only began to show significant improvement after an incidental finding of Whipple’s disease. Due to its rare nature, other instances of the disease have likely gone undiagnosed. A brief review of relevant literature is also included.

  • Open Access

    2822. Impact of Restrictive Urinalysis Reflex to Culture Criteria at a Large Community Hospital

    by Christian F Caveness, Alison Orvin, Jeannette Bouchard

    Treatment of asymptomatic bacteriuria (ASB) is a common, but often unnecessary, practice. Some data suggest increased rates of positive urine cultures (UC) lead to ASB treatment. The objective of this study was to determine the impact of restrictive urinalysis reflex to culture (UARC) criteria on rate of UCs ordered and ASB treatment. Previous UARC criteria were any of the following: leukocyte esterase trace or greater, positive nitrites, or white blood cells (WBC) > 10 cells/high powered field (HPF). On March 15, 2023, the criteria were modified to only WBC > 10 cells/HPF. This was a pre-post study evaluating UARCs ordered in the emergency department or inpatient units from March 1 to March 31, 2022 (pre-intervention) and March 16 to April 15, 2023 (post-intervention). The primary outcome was the proportion of reflex UCs prevented. Secondary outcomes included the frequency of repeat UARCs and stand-alone UCs ordered after an initial negative UARC, the incidence of patients with gram-negative rod (GNR) bacteremia within 7 days of a negative UARC, and the rate of ASB treatment in a sample of patients with positive UCs after UARC. In the pre-intervention, 4761 UARCs were ordered compared to 5420 in the post-intervention; 1806 (37.9%) and 1160 (21.4%) reflexed to UCs, leading to a 43.5% reduction in UCs. The rate of repeat UARCs, stand-alone UCs, and rates of GNR bacteremia with a negative UARC were numerically similar between groups. In the sample of pre-intervention patients (n = 100), 70 were women, median age was 74 years old (IQR 61-82), and median Charlson comorbidity index (CCI) was 5 (IQR 2-6). In total, 83 patients with positive UCs were treated, 43 (51.5%) were asymptomatic. In the post-intervention (n=68), 54 (79.4%) were women, median age was 80 (IQR 64-85), and median CCI was 5 (IQR 4-6). Fifty-five (80.9%) patients were treated, 24 (43.6%) were asymptomatic. The change in UARC criteria led to a 43.5% relative reduction in UCs. A similar number of patients in the post-intervention and the pre-intervention had GNR bacteremia without a reflex UC. ASB treatment rate was lower in the post-intervention; more studies are needed to determine the true effect of restrictive UARC criteria on ASB treatment. All Authors: No reported disclosures

  • Open Access

    1211. Impact of Gram-Negative Rod Bacteremia Rapid Diagnostic Testing and Real-Time Clinical Staff Pharmacist Review

    by Abby Kremer, Alison Orvin

    Although Rapid Diagnostic Testing (RDT) enables optimization of antimicrobial therapy, there is no consensus on how to integrate utilization into clinical practice. At our institution, the BIOFIRE® Blood Culture Identification 2 (BCID2) RDT was implemented in September 2021 in conjunction with real-time clinical staff pharmacist result notification and review. The objective of this study was to determine the impact of RDT plus real-time clinical staff pharmacist review on the management of gram-negative rod (GNR) bacteremia. This retrospective, matched cohort study included patients with a positive blood culture for a GNR on the BCID2 panel from September 2020 to August 2021 (historical) and October 2021 to September 2022 (interventional). Exclusion criteria were polymicrobial bacteremia, discrepant RDT results from traditional culture, 24-hour mortality, and comfort care or not admitted at the time of RDT result. Patients were randomly screened to include 120 patients in each group and matched based on age, pathogen, and resistance mechanism. The primary endpoint was time from Gram stain to appropriate antibiotic therapy. Secondary endpoints included time to first pathogen-directed change in therapy, days of anti-pseudomonal therapy, length of stay (LOS), and inpatient mortality. The study population was predominantly female (61%) and the majority were over 70 years old (55%). Escherichia coli was isolated in 71% of patients with extended-spectrum beta-lactamase-producing organisms isolated in 8%. The median time to appropriate therapy was 0 hours for both groups, indicating patients were on appropriate therapy at the time of Gram stain result (p=0.28). There was a statistically significant decrease in time to first pathogen-directed change in therapy (40 vs. 11 hours; p< 0.01). There was no difference in days of anti-pseudomonal therapy, LOS, or inpatient mortality between groups. Implementation of RDT plus real-time clinical staff pharmacist intervention did not impact time to appropriate therapy in patients with GNR bacteremia but did significantly reduce time to pathogen-directed antibiotic changes. RDT plus real-time clinical staff pharmacist intervention is a practical method of utilizing technology to improve patient care. All Authors: No reported disclosures

  • Impact of Gram-Negative Rod Bacteremia Rapid Diagnostic Testing and Real-Time Clinical Pharmacist Intervention

    by Abby M. Kremer, Jeannette L. Bouchard, Alison I. Orvin

    Background: The optimal method for implementing rapid diagnostic testing (RDT) into clinical practice has not been determined for gram-negative rod (GNR) bacteremia. At our institution, RDT was implemented in conjunction with real-time notification of results to decentralized clinical pharmacists. Objective: To determine the impact of RDT result notification plus real-time clinical pharmacist review on the management of GNR bacteremia. Methods: This retrospective, matched cohort study included patients with a positive blood culture for a GNR on the BIOFIRE® Blood Culture Identification 2 panel from September 2020 to August 2021 (historical) and October 2021 to September 2022 (interventional). Exclusion criteria were polymicrobial bacteremia, discrepant RDT results from traditional culture, 24-hour mortality, and comfort care or not admitted at the time of RDT result. Patients were matched based on age, pathogen, and resistance. The primary endpoint was time from Gram stain to appropriate antibiotic therapy. Results: This study consisted of 240 patients (n = 120 historical, n = 120 interventional). Escherichia coli was isolated in 71% of patients with extended-spectrum beta-lactamase-producing organisms isolated in 8%. There was no difference in median time to appropriate therapy (0 vs 0 hours, P = 0.28). There was a statistically significant decrease in time to first organism-directed change in therapy (40 vs 11 hours; P < 0.01). Length of stay, days of anti-pseudomonal therapy, and inpatient mortality did not differ between groups. Conclusion: Implementation of RDT plus real-time clinical pharmacist review did not significantly decrease time to appropriate therapy in patients with GNR bacteremia but significantly reduced time to organism-directed antibiotic changes.